Feb 8 (Reuters) - Innovent Biologics Inc <1801.HK>::
*INNOVENT ANNOUNCES STRATEGIC COLLABORATION WITH LILLY TO DEVELOP NEW MEDICINES GLOBALLY IN ONCOLOGY AND IMMUNOLOGY
*INNOVENT BIOLOGICS - INNOVENT WILL RECEIVE A $350 MILLION UPFRONT PAYMENT
*INNOVENT BIOLOGICS: IS ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY & COMMERCIAL MILESTONE PAYMENTS UP TO EST $8.5 BILLION CONTINGEN CERTAIN FUTURE EVENTS
*: INNOVENT ANNOUNCES STRATEGIC COLLABORATION WITH LILLY TO DEVELOP NEW MEDICINES GLOBALLY IN ONCOLOGY AND IMMUNOLOGY
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 08-FEB-202610:05:00.027 GMT